PharmEasy Unlisted Share Price Description –
PharmEasy-parent API Holdings is India’s largest digital healthcare platform which operates an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages-
A. providing digital tools and information on illness and wellness
B. offering teleconsultation
C. offering diagnostics and radiology tests
D. delivering treatment protocols including products and devices
API Holdings has built a technology platform that connects the dots across the healthcare value chain. That means it works closely with everyone from consumers to pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors, clinics, and diagnostic labs. By being present in India and taking a connected ecosystem approach—and offering a range of services that complement each other—API Holdings has built strong relationships throughout the healthcare value chain. That includes wholesalers, chemists, consultants, consumers, and other businesses.
PharmEasy plans to relaunch its IPO in 2025. That’s about two years after it first withdrew its application. The company will present its IPO strategy to its board next month. One option on the table is a reverse merger with its publicly listed subsidiary, Thyrocare. PharmEasy wants to use that improved cash flow—and a fresh business model—to attract investors.
What is PharmEasy?
PharmEasy is a consumer healthcare ‘super app’ that lets users order prescription medications, over-the-counter pharmaceuticals and other healthcare products to be delivered right to their homes. On top of that, it offers diagnostic testing services and teleconsultations. That means it can really address a wide range of healthcare needs for its consumers.
Read Also: Sterlite Power Unlisted Shares
Products & Services of PharmEasy
- Prescription Medications
- Over-the-Counter (OTC) Products
- Diagnostic Services
- Teleconsultations
- Health Packages
- Home Delivery
- User-Friendly Mobile App
PharmEasy Subsidiaries Companies
- API Holdings Limited (Holding Company)
- Threpsi Solutions Private Ltd.
- AKP Healthcare Private Ltd.
- Eastern Agencies Healthcare Private Ltd.
- Venkatesh Medico Private Ltd.
- Aushad Pharma Distributors Private Limited
- Avighna Medicare Private Limited
- Aycon Graph Connect Private Limited
- Aryan Wellness Private Limited
- Ayro Retail Solutions Private Ltd.
- D.C Agencies Private Limited
- Mahaveer MediSales Private Limited
- Docon Technologies Private Ltd.
- Ascent Wellness and Pharma Solutions Private Ltd.
- Reenav Pharma Private Limited
- AHWSPL India Private Limited
- Thyrocare Technologies Limited
- Akna Medical Private Limited
Key Highlights – FY 2023 – 24
- The company is expanding its product business in semi-urban and rural markets across India.
- PharmEasy’s revenue from operations declined by 14.75%, dropping to INR 5,664.2 crore in FY 2024, compared to INR 6,643.9 crore in FY 2023.
- PharmEasy’s total expenditure decreased by 19.16%, falling to INR 7,254.8 crore in FY 2024 from INR 8,974 crore in FY 2023.
- Deeper penetration into Tier-2 & Tier 3 cities
- In FY 2024, PharmEasy generated INR 5,008 crore from the sale of medicines, while revenue from lab tests and other services amounted to INR 652 crore.
Read Also: Biggest Unlisted Companies in India
API Holdings Board of Directors
- Mr. Siddharth Shah, MD & CEO
- Dr. Dhaval Shah, Whole-time Director
- Mr. Hardik Dedhia, Whole-time Director
- Mr. Shyam Powar, Non-Executive Director
- Dr. Ranjan Pai, Non-Executive Director
- Mr. Dovaldas Buzinskas, Non-Executive Director
- Mr. Aditya Puri, Chairman, Non-Executive Director
- Mr. Deepak Vaidya, Independent, Non-Executive Director
- Mr. Ankur Thadani, Non-Executive Director
- Mr. Ashutosh Sharma, Non-Executive Director
- Ms. Vineeta Rai, Independent, Non-Executive Director
- Dr. Jaydeep Tank, Independent, Non-Executive Director
- Mr. Subramaniam Somasundaram, Independent, Non-Executive Director
PharmEasy Unlisted Share Price Details
| Name | API Holdings Unlisted Share Price Details |
| Face Value | INR 1 per share |
| ISIN Code | INE0DJ201029 |
| Lot Size | 1,000 shares |
| Demat Status | NSDL, CDSL |
| API Holdings Share Price | INR 7.90 per share |
| Market Cap | INR 4,930 crore |
| Total number of shares | 6,24,04,35,432 shares |
| Website | www.pharmeasy.in |
PharmEasy Unlisted Share Price – Shareholding Pattern
Details of shareholders holding more than 5% of a class of equity shares in the company:
| Shareholder Name | % to Holding | No. of shares |
| Naspers Ventures B. V. | 13.03 | 81,33,16,570 |
| MacRitchie Investments Pte. Ltd. | 11.74 | 73,25,16,290 |
| TPG Growth V SF Markets Pte. Ltd | 7.20 | 44,94,92,340 |
| Evermed Holdings Pte. Ltd. | 6.35 | 39,60,33,000 |
| Prasid Uno Family Trust through its trustee Surbhi Singh | 4.39 | 27,39,83,731 |
| Others | 57.29 | 3,57,50,93,501 |
PharmEasy Unlisted Share Price – Financial Metrics
| Particulars | FY 2022 | FY 2023 | FY 2024 |
| Revenue | 5,728.82 | 6,643.94 | 5,664.29 |
| Expenses | 8,491.59 | 8,974.01 | 7,254.80 |
| Net income | (3,992.50) | (5,211.73) | (2,533.51) |
| Margin (%) | (69.69) | (78.44) | (44.73) |
| ROCE (%) | – | (92.0) | (29.0) |
| EBITDA (%) | (40.18) | (23.40) | (11.41) |
| EPS | (7.28) | (8.51) | (4.07) |
| Debt/Equity | – | 0.01 | 0.60 |
Read Also: Best IPOs That Doubled Investors’ Money
PharmEasy Annual Reports
PharmEasy Annual Report FY 2023 – 2024
PharmEasy Annual Report FY 2021 – 2022
PharmEasy Draft Red Herring Prospectus
PharmEasy Unlisted Share Price – Peer Comparison
| Company | 3-yr Sales CAGR (%) | ROCE (%) | Net Margin (%) | MCap (INR Cr.) |
| PharmEasy (API Holdings) | 34.36 | (29.0) | (44.73) | 4,930 |
| Apollo Hospitals (Apollo Pharmacy) | 21.8 | 15.1 | 4.91 | 95,948 |
PharmEasy Unlisted Share FAQs
Is it safe to purchase unlisted shares in India?
While there are risks associated with unlisted shares, purchases made from credible brokers and after conducting due diligence considerably lower these risks.
What is API Holding share price?
PharmEasy unlisted share price today is INR 9.40 per share. Shares are purchased in lots of 1,000 shares.
Who determines PharmEasy share price?
The unlisted share price is determined by various factors including recent transaction price, supply and demand, valuation in the latest funding round, profitability, and return ratios.
What are PharmEasy IPO 2025 plans, and when is the relaunch expected?
PharmEasy plans to revisit its initial public offering (IPO) plans at its board meeting in May 2025. The company is looking to relaunch the IPO after pulling its application a couple of years ago.